Abstract
Mitochondrial dysfunction and neuroinflammation occur in Alzheimer’s disease (AD). The causes of these pathologic lesions remain uncertain, but links between these phenomena are increasingly recognized. In this review, we discuss data that indicate mitochondria or mitochondrial components may contribute to neuroinflammation. While mitochondrial dysfunction could cause neuroinflammation, neuroinflammation could also cause mitochondrial dysfunction. However, based on the systemic nature of AD mitochondrial dysfunction as well as data from experiments we discuss, the former possibility is perhaps more likely. If correct, then manipulation of mitochondria, either directly or through manipulations of bioenergetic pathways, could prove effective in reducing metabolic dysfunction and neuroinflammation in AD patients. We also review some potential approaches through which such manipulations may be achieved.
Keywords: Alzheimer’s disease, Bioenergetics, Damage associated molecular pattern, Inflammation, Mitochondria.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Relationships Between Mitochondria and Neuroinflammation: Implications for Alzheimer’s Disease
Volume: 16 Issue: 8
Author(s): Heather M. Wilkins and Russell H. Swerdlow
Affiliation:
Keywords: Alzheimer’s disease, Bioenergetics, Damage associated molecular pattern, Inflammation, Mitochondria.
Abstract: Mitochondrial dysfunction and neuroinflammation occur in Alzheimer’s disease (AD). The causes of these pathologic lesions remain uncertain, but links between these phenomena are increasingly recognized. In this review, we discuss data that indicate mitochondria or mitochondrial components may contribute to neuroinflammation. While mitochondrial dysfunction could cause neuroinflammation, neuroinflammation could also cause mitochondrial dysfunction. However, based on the systemic nature of AD mitochondrial dysfunction as well as data from experiments we discuss, the former possibility is perhaps more likely. If correct, then manipulation of mitochondria, either directly or through manipulations of bioenergetic pathways, could prove effective in reducing metabolic dysfunction and neuroinflammation in AD patients. We also review some potential approaches through which such manipulations may be achieved.
Export Options
About this article
Cite this article as:
Wilkins M. Heather and Swerdlow H. Russell, Relationships Between Mitochondria and Neuroinflammation: Implications for Alzheimer’s Disease, Current Topics in Medicinal Chemistry 2016; 16 (8) . https://dx.doi.org/10.2174/1568026615666150827095102
DOI https://dx.doi.org/10.2174/1568026615666150827095102 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NAD+ Metabolism and NAD+-Dependent Enzymes: Promising Therapeutic Targets for Neurological Diseases
Current Drug Targets Strategies of overcoming the physiological barriers for tumor-targeted nano-sized drug delivery systems
Current Pharmaceutical Design Pisosterol Induces G2/M Cell Cycle Arrest and Apoptosis via the ATM/ATR Signaling Pathway in Human Glioma Cells
Anti-Cancer Agents in Medicinal Chemistry Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets The Role of Integrins in Glioma Biology and Anti-Glioma Therapies
Current Pharmaceutical Design 99mTc-labeling of Peptidomimetic Antagonist to Selectively Target αvβ3 Receptor-Positive Tumor: Comparison of PDA and EDDA as Co-Ligands
Current Radiopharmaceuticals Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)
Current Pharmacogenomics Biomimetic Drug Delivery Systems Oriented by Biological Function in Tumor Targeting
Current Drug Targets Stimuli-Responsive Nanoparticles for siRNA Delivery
Current Pharmaceutical Design Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry Microenvironmental Regulation of Cancer Stem Cell Phenotypes
Current Stem Cell Research & Therapy Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights
Current Neuropharmacology Cucurbitacin E, An Experimental Lead Triterpenoid with Anticancer, Immunomodulatory and Novel Effects Against Degenerative Diseases. A Mini-Review
Current Topics in Medicinal Chemistry Cellular Efflux of cAMP and cGMP - A Question about Selectivity
Mini-Reviews in Medicinal Chemistry Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design Inorganic Nanoparticles for Enhanced Photodynamic Cancer Therapy
Current Drug Discovery Technologies Exosomes Harnessed as Nanocarriers for Cancer Therapy - Current Status and Potential for Future Clinical Applications
Current Molecular Medicine Meet Our Editorial Board Member
Current Drug Discovery Technologies Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Current Neuropharmacology PPARγ and Early Human Placental Development
Current Medicinal Chemistry